doi: 10.1016/j.ccell.2020.06.001 [DOI] [PMC free article] [PubMed] [Google Scholar] 20
Figure 1 illustrates the pharmacological potential of NLRP3 inhibition in the context of other approved and investigational approaches that modulate cytokine release, driving chronic inflammation
Treatment time depends on your specific case, but most patients finish in about 1224 months
To generate mutations at the APTF-2 target site in the glp-1 promoter we injected the following mix: Cas9 protein (5 g), tracrRNA (0.4 g/l), crRNA (aatgggcggagtatgccacc) (0.4 g/l), ssDNA oligo repair donor (1 g/l), myo-2::mCherry plasmid (4 ng/l) and brought to a 20 l volume with nuclease-free water
This early conditioning can contribute to long-term unhealthy eating habits, increasing the risk of obesity and related metabolic dysfunction
Patients with obesity may be appropriately treated with diabetes-approved GLP-1 RAs if they also have a diagnosis of T2DM, though claims data may not fully capture this information
